Back to top
more

Seattle Genetics, Inc. (SGEN)

(Delayed Data from NSDQ)

$67.25 USD

67.25
574,388

+0.33 (0.49%)

Updated May 3, 2019 04:00 PM ET

After-Market: $67.27 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Pfizer's (PFE) Q2 Earnings Beat, Sales Miss, Stock Declines

by Zacks Equity Research

Pfizer (PFE) beats estimates for second-quarter earnings but misses the same for sales. It trims the upper end of its revenue guidance range for 2023. Stock falls.

Seattle Genetics (SGEN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Seattle Genetics (SGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

by Zacks Equity Research

Sector ETF report for FBT

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FBT

Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for EUSA

Lava (LVTX) Discontinues Hematological Tumor Study, Shares Fall

by Zacks Equity Research

Lava (LVTX) falls 10% due to its decision to discontinue the study on LAVA-051, which is being evaluated for multiple hematological tumors. The company shifts focus to LAVA-1207 in the prostate cancer study.

LAVA (LVTX) Up on J&J's (JNJ) Cancer Study Candidate Selection

by Zacks Equity Research

LAVA's (LVTX) shares soar as partner J&J (JNJ) selects a lead candidate for development in clinical studies for cancer.

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

by Zacks Equity Research

Sector ETF report for FBT

Kinjel Shah headshot

Pharma Stock Roundup: FDA Nod to ABBV's Rinvoq for New Indication & Other Updates

by Kinjel Shah

FDA panel votes in favor of Pfizer's (PFE) experimental maternal RSV vaccine. FDA approves AbbVie's (ABBV) Rinvoq for Crohn's Disease.

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FBT

Pfizer (PFE) to Raise $31B in Debt to Fund Seagen (SGEN) Deal

by Zacks Equity Research

Pfizer (PFE) offers bonds worth $31 billion to fund its pending acquisition of cancer drugmaker, Seagen (SGEN).

Stock Market News for May 17, 2023

by Zacks Equity Research

U.S. stock markets closed lower on Tuesday following weak earnings results of a retail supergiant.

FTC May Reportedly Block Amgen's (AMGN) $28B Horizon Buyout

by Zacks Equity Research

Unconfirmed reports suggest that the FTC may challenge the $28-billion buyout of Horizon Therapeutics (HZNP) by Amgen.

Neena Mishra headshot

Biotech ETFs Pop on M&A Resurgence

by Neena Mishra

2023 could be a year of heightened biotech dealmaking activity

Pfizer (PFE) Q1 Earnings Beat, COVID Jab Sales Down as Expected

by Zacks Equity Research

Pfizer (PFE) beats estimates for Q1 earnings and sales. Revenues from its COVID-19 vaccine, Comirnaty declined, as expected.

Will Pfizer (PFE) Beat Expectations This Earnings Season?

by Zacks Equity Research

Higher alliance revenues from Eliquis, higher sales of Prevnar vaccines and drugs like Vyndaqel/Vyndamax are likely to have contributed to Pfizer's (PFE) sales growth in Q1.

Seagen's (SGEN) Q1 Earnings and Revenues Miss Expectations

by Zacks Equity Research

Seagen (SGEN) reports worse-than-expected results in the first quarter of 2023, missing both earnings and sales estimates.

Seattle Genetics (SGEN) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Seattle Genetics (SGEN) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Seattle Genetics (SGEN) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Seattle Genetics (SGEN) delivered earnings and revenue surprises of -13.41% and 0.23%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Will Jakafi Sales Drive a Beat For Incyte (INCY) Q1 Earnings?

by Zacks Equity Research

Incyte's (INCY) first-quarter 2023 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.

Ocuphire (OCUP) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Occuphire (OCUP) is expected to provide updates on its proprietary ophthalmic platform for treating refractive and retinal eye disorders, on its first-quarter earnings call.

Repligen (RGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

by Zacks Equity Research

Repligen (RGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Zacks Analyst Blog Highlights J&J, AstraZeneca, Merck, Seagen and Pfizer

by Zacks Equity Research

J&J, AstraZeneca, Merck, Seagen and Pfizer are part of the Zacks Top Analyst Blog.

Kinjel Shah headshot

Pharma Stock Roundup: J&J's $8.9B Offer for Talc Litigation Settlement & Other Updates

by Kinjel Shah

J&J (JNJ) offers a $8.9 billion settlement to resolve its talc lawsuits. FDA approves Merck's (MRK) Keytruda plus Seagen's Padcev for a bladder cancer indication.

Seagen's (SGEN) Padcev & Keytruda Combo Gets FDA Accelerated Nod

by Zacks Equity Research

The FDA grants accelerated approval to Seagen (SGEN) and partner, Astellas' combination therapy of Padcev with Merck's Keytruda for the treatment of first and second-line metastatic urothelial cancer.